Kolmar Group Participates in 250 Billion KRW Investment Fund... "Fostering New Growth Engines"

[Asia Economy Reporter Jeon Jinyoung] Kolmar Group announced on the 26th that it will participate as the sole investing company in a global investment fund worth a total of 250 billion KRW established by KB Investment. This is to discover bio and platform companies and expand new growth engines.

The fund being established this time will be managed by KB Investment, a subsidiary of KB Financial Group. Kolmar Group’s five companies?Korea Kolmar Holdings, Korea Kolmar, HK Innoen, Kolmar BNH, and Yeonwoo?will each invest 10 billion KRW, totaling 50 billion KRW. The plan is to invest in promising bio ventures and commerce companies mainly in the United States, where the pharmaceutical bio industry is growing rapidly, as well as in India and Southeast Asia.

The highest investment proportion is in companies based in the United States. This is because the U.S. treatment and digital healthcare markets have been expanding due to the COVID-19 pandemic.

In India and Southeast Asia, where IT platform growth is rapid, investments will focus intensively on commerce and healthcare platform companies. The middle class in India and Southeast Asia is continuously increasing, and the digital economy system is spreading, leading to rapid growth in digital technology capabilities.

A representative of Korea Kolmar Holdings said, "We are pleased to have the opportunity to partner with KB Investment, a top-tier domestic investment institution, to discover and invest in global companies. We expect to explore various investment opportunities in promising fields that will lead future markets."

Meanwhile, Korea Kolmar Holdings is expanding its investments in promising bio venture companies both domestically and internationally. Following last year’s investments in immune and anticancer drug development companies such as GI Cell, Cell in Cells, and Novacell Technology, this year it acquired shares in the digital healthcare platform Allround Doctors and AI endoscopy development company Dain Medical Group.